Ivonescimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Ivonescimab Usage And Synthesis

Uses

Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research[1][2][3].

References

[1] Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9:
[2] Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10:
[3] Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517.

Ivonescimab(2428381-53-5)Related Product Information

• Bafisontamab
• Geptanolimab
• Rinucumab
• Immunoglobulin M,anti-(human CD147 (antigen)) (mouse monoclonal ABX-CBL m-chain), disulfide with mousemonoclonal ABX-CBL light chain, pentamer
• Tregalizumab
• Depemokimab
• Biciromab
• Vilobelimab
• Dusigitumab
• Abrezekimab